Pfizer And Eisai Will Continue To Promote Aricept, But Add Lyrica To The Collaboration
This article was originally published in The Pink Sheet Daily
Executive Summary
After Eisai tried to get out of its co-promotion deal for the Alzheimer’s disease blockbuster, the two companies settle their dispute with Japanese rights to Aricept returning to Eisai sooner than originally planned.
You may also be interested in...
Eisai/Pfizer Get U.S. FDA Complete Response For Alzheimer's Patch
Eisai Inc. announced April 25 that FDA has issued a "complete response" for the transdermal patch version of its best-selling drug Aricept (donepezil) for Alzheimer's disease
Eisai/Pfizer Get Complete Response For Alzheimer's Patch
FDA wants more details about the Aricept patch before it issues an approval.
Eisai/Pfizer Get Complete Response For Alzheimer's Patch
FDA wants more details about the Aricept patch before it issues an approval.